Ho Chi Minh City, Vietnam – June 27, 2024 – Imexpharm (IMP) welcomed over 20 shareholders, investment funds, and securities company representatives to its IMP2 high-tech antibiotic factory located in Vinh Loc Industrial Park. IMP2 is one of 3 EU-GMP factories of the Company, featuring advanced technology and production standards.
"Established in 1977, Imexpharm has consistently prioritized investment in international-standard production” said Le Thanh Hang – Imexpharm’s IR Director. “Today, we have 3 EU-GMP factories with 11 EU-GMP production lines. These achievements reflect our strong financial foundation, consistent investments in technology, human resources, and robust R&D activities”.
Hang further emphasized: “In Vietnam, Imexpharm is the only pharmaceutical company with 11 EU-GMP production lines, solidifying our leadership in high-quality antibiotic production. This is a competitive edge that other domestic pharmaceutical companies will need to invest significant time and resources to match. With our vision and mission to provide effective healthcare solutions to the community, Imexpharm remains committed to expanding world class production and people development.”
The tour provided a comprehensive overview of Imexpharm's EU-GMP factories, organizational structure, manufacturing plant management and future strategies.
Visitors expressed strong interest in Imexpharm's business and its growth trajectory in the upcoming years.
This EU-GMP factory tour exemplified Imexpharm’s dedication to investor relations. The Company is committed to providing shareholders and investors with timely, thorough, and transparent information on its business and operations. IMP stock closed at VND 75,300/share on June 28, 2024, up 33% year-to-date with an average daily trading volume over the latest 10 trading sessions of ~60,000 shares.
For further details, please contact:
Investor Relations Department
Email: ir@imexpharm.com
Address: 24th Floor, Flemington Tower, 182 Le Dai Hanh Street, Ward 15, District 11, Ho Chi Minh City